论文部分内容阅读
背景与目的随着女性肺癌发病率的攀升,其独特的临床和流行病学特征及良好预后引起了学界的关注。本研究通过回顾性分析女性晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的临床资料,探讨其预后相关因素。方法收集541例女性晚期NSCLC患者的临床资料,并随访至死亡。主要观察指标为总生存(overallsurvival,OS)。采用SPSS11.0统计软件进行生存分析。结果全组腺癌占80.2%(434/541),总体中位OS为15个月(95%CI:13.87-16.13),1年、2年、5年生存率分别为58.8%、23.7%和3.20%。单因素分析显示,临床分期、ECOG评分、体重下降、临床症状、血行转移和一线治疗后化疗方案数>1、一线化疗有效、曾接受靶向治疗或放疗均与中位OS明显相关(P值均<0.05)。治疗前体重下降、ECOG评分、靶向治疗及一线化疗有效为生存的独立预后因素(P值均<0.05)。结论女性晚期NSCLC患者的病理类型以腺癌为主,体重下降、ECOG评分、接受靶向治疗及一线化疗有效可能成为女性晚期NSCLC患者生存的独立预后指标。
Background and Objective With the rising incidence of lung cancer in women, its unique clinical and epidemiological characteristics and good prognosis have drawn the attention of academic circles. This study retrospectively analyzed the clinical data of women with advanced non-small cell lung cancer (NSCLC) and explored the prognostic factors. Methods Clinical data of 541 women with advanced NSCLC were collected and were followed up until their death. The main observation index was overallsurvival (OS). Survival analysis using SPSS11.0 statistical software. The overall median OS was 15 months (95% CI: 13.87-16.13). The 1-year, 2-year and 5-year survival rates were 58.8% and 23.7%, respectively 3.20%. Univariate analysis showed that the first-line chemotherapy was effective in first-line chemotherapy, clinical staging, ECOG score, weight loss, clinical symptoms, hematogenous metastasis and first-line chemotherapy. The patients who received targeted therapy or radiotherapy had a significant correlation with median OS All <0.05). Pretreatment weight loss, ECOG score, targeted therapy and first-line chemotherapy were independent prognostic factors for survival (P <0.05). Conclusions The pathological type of advanced NSCLC is adenocarcinoma. The weight loss, ECOG score, targeted therapy and first-line chemotherapy may be the independent prognostic indicators for the survival of women with advanced NSCLC.